- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
- Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
More ▼
Key statistics
On Friday, Monopar Therapeutics Inc (MNPR:NAQ) closed at 0.6582, 140.31% above the 52 week low of 0.2739 set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.63 |
---|---|
High | 0.6671 |
Low | 0.63 |
Bid | 0.65 |
Offer | 0.679 |
Previous close | 0.6275 |
Average volume | 78.84k |
---|---|
Shares outstanding | 17.45m |
Free float | 8.32m |
P/E (TTM) | -- |
Market cap | 11.49m USD |
EPS (TTM) | -0.612 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:58 BST.
More ▼